Navigating Complex Drug Development.

Optimizing Portfolio Value.

ABOUT

Why Switchback BioStrategy Group?

Navigating the Ascent. Managing the Uncertainty.
In early drug development, the path to commercialization is rarely a straight line – it requires strategic switchbacks to navigate steep scientific, regulatory, clinical and financial hurdles and terrain.

Switchback BioStrategy Group provides cross-functional strategic guidance and project leadership for biotechnology and pharmaceutical innovators, moving assets efficiently from preclinical discovery through global commercialization.

Driven by a unique combination of deep roots across multiple therapeutic areas, rigorous statistical / analytic evaluations, precision planning and decades of biopharma executive leadership and asset management.

Learn More

What we do

our core capabilities

Executive Project Management & Program Leadership

Tailored project management strategies to drive assets from discovery to global commercialization effectively.

Regulatory & Clinical Execution

Comprehensive regulatory strategies ensuring successful submissions and compliance throughout the drug development lifecycle.

Strategic Planning & Asset Valuation

Enhanced productivity through process optimization, reducing redundancies, and implementing metrics for success.

Broad Therapeutic Footprint

Extensive global development and strategy experience across high-stakes therapeutic areas, including:

• Biosimilars
• Cardiovascular
• CNS & Neurodegenerative
• Dermatology
• Endocrinology
• Gastroenterology
• General Medicine
• Immunology
• Infectious Diseases
• Metabolic
• Neuroscience
• Oncology
• Radiopharmaceuticals
• Respiratory
• Rheumatology
• Urology

No matter your therapeutic focus, Switchback BioStrategy Group brings specialized insight and proven execution to your program.

Learn more

michael miernicki 1 — Michael Miernicki, Ph.D.

Meet Our Principal & Founder

Dr. Michael Miernicki is a veteran biotechnology and pharmaceutical executive with nearly four decades of success driving global drug development and process transformation. Melding a rigorous background in neuroscience and statistics with senior vice president leadership roles, he brings a unique cross-functional lens to drug asset commercialization Throughout his career at leading innovators (Amgen, Bristol-Myers Squibb, Johnson & Johnson), private- and publicly-funded biotech start-ups (Perspective Therapeutics, KBP Biosciences, Drais Pharmaceuticals, GPC Biotech, FIDIA Pharmaceuticals) and premier global CROs (ICON, Worldwide Clinical Trials), Dr. Miernicki has built elite project management infrastructures, scaled cross-functional teams, and optimized R&D portfolios. He specializes in translating complex clinical data into robust, risk-mitigated corporate strategy.

Connect with Dr. Miernicki on LinkedIn

Partner with Switchback BioStrategy Group to bring clarity, efficiency and clinical precision to your drug development portfolio.

Let’s Strategize Your Next Milestone

Get Started Today

Learn More